Regional pharmacokinetics of amifostine in anesthetized dogs: Role of the liver, gastrointestinal tract, lungs, and kidneys

Drug Metabolism and Disposition

Volumn 30, Issue 12, 2002, Pages 1425-1430

  Levi, Micha ^a,b   Knol, James A ^a   Ensminger, William D ^b,c   Deremer, Susan J ^b   Dou, Chunzhi ^b   Lunte, Susan M ^d   Bonner, Heather S ^e   Shaw, Leslie M ^e   Smith, David E ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b PFIZER INC   (United States)

^c UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF KANSAS   (United States)

^e Laboratory Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; ACEPROMAZINE MALEATE; ALKALINE PHOSPHATASE; AMIFOSTINE; ATROPINE; CISPLATIN; PENTOBARBITAL; PRODRUG; PROTECTIVE AGENT; ANESTHETIC AGENT;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD FLOWMETRY; CELL PROTECTION; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ISOLATION; DRUG SELECTIVITY; DRUG TISSUE LEVEL; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; KIDNEY; LIVER; LUNG; NONHUMAN; PRIORITY JOURNAL; STEADY STATE; ANIMAL; ANTIBODY SPECIFICITY; BLOOD FLOW; DIGESTIVE SYSTEM; DRUG EFFECT; FEMALE; MALE; METABOLIC CLEARANCE RATE; METABOLISM; PHYSIOLOGY; VASCULARIZATION;

ANIMALIA; CANIS FAMILIARIS;

AMIFOSTINE; ANESTHETICS; ANIMALS; DIGESTIVE SYSTEM; DOGS; FEMALE; KIDNEY; LIVER; LUNG; MALE; METABOLIC CLEARANCE RATE; ORGAN SPECIFICITY; REGIONAL BLOOD FLOW;

EID: 1842833748     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: 10.1124/dmd.30.12.1425     Document Type: Article

References (28)

1. Altman PL and Dittmer DS (1974) Bilogy Data Book. 2nd Ed., vol III. Federation of American Societies for Experimental Biology, Bethesda, MD
2. Bonner HS and Shaw LM (2002) New dosing regimens for amifostine: A pilot study to compare the relative bioavailability of oral and subcutaneous administration with intravenous infusion. J Clin Pharmacol 42:166-174.
3. Capizzi RL (1996) The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine (ethyol®). Eur J Cancer 32A (Suppl 4):S5-S16.
4. Culy CR and Spencer CM (2001) Amifostine: An update on its clinical status as a cytoprotectant in patients with cancer receiving chemotherapy or radiotherapy and its potential therapeutic application in myelodysplastic syndrome. Drugs 61:641-684.
5. Foster-Nora JA and Siden R (1997) Amifostine for protection from antineoplastic drug toxicity. Am J Health Syst Pharm 54:787-800.
6. Gibaldi M and Perrier D (1982) Pharmacokinetics. 2nd Ed., Marcel Dekker, New York.
7. Jirtle RL, Ancher MS, and Alati T (1990) Radiation sensitivity of the liver, in Advances in Radiation Biology (Lett JT and Altman KI eds) vol 14, pp 269-311, Academic Press, San Diego.
8. Jirtle RL, Pierce LJ, Crocker IR, and Strom SC (1985) Radiation protection of rat parenchymal hepatocytes with S-2-(3-aminopropylamino)ethylphosphorothioic acid. Radiother Oncol 4:231-237.
9. Korst AEC, Eeltink CM, Vermorken JB, and van der Vijgh WJF (1997) Pharmacokinetics of amifostine and its metabolites in patients. Eur J Cancer 33:1425-1429.
10. Kuan H-Y, Smith DE, Ensminger WD, Knol JA, DeRemer SJ, Yang Z, and Stetson PL (1996) Regional pharmacokinetics of 5-bromo-2′-deoxyuridine and 5-fluorouracil in dog: Hepatic arterial vs. portal venous infusions. Cancer Res 56:4724-4727.
11. Kuan H-Y, Smith DE, Ensminger WD, Knol JA, DeRemer SJ, Yang Z, and Stetson PL (1998) Regional pharmacokinetics of 5-fluorouracil in dogs: Role of the liver, gastrointestinal tract and lungs. Cancer Res 58:1688-1694.
12. Mangold DJ, Miller MA, Huelle BK, Sanchez-Barona DOT, Swynnerton NF, Fleckenstein L, and Ludden TM (1989) Disposition of the radioprotector ethiofos in the rhesus monkey: Influence of route of administration. Drug Metab Dispos 17:304-310.
13. McComb RB, Bowers GN Jr, and Posen S (1979) Alkaline Phosphatase. Plenum Press, New York.
14. Physicians' Desk Reference (2002) Ethyol®, pp 2029-2031, Medical Economics Company Inc., Montvale.
15. Ridge JA, Bading JR, Gelbard AS, Benua RS, and Daly JM (1987) Perfusion of colorectal hepatic metastases: Relative distribution of flow from the hepatic artery and portal vein. Cancer 59:1547-1553.
16. Shaw LM, Bonner HS, and Brown DQ (1994b) Metabolic pathways of WR-2721 (ethyol, amifostine) in the BALB/c mouse. Drug Metab Dispos 22:895-902.
17. Shaw LM, Bonner H, and Lieberman R (1996) Pharmacokinetic profile of amifostine. Semin Oncol 23 (Suppl 8):18-22.
18. Shaw L, Bonner H, Nakashima H, and Lieberman R (1994a) Pharmacokinetics of amifostine in cancer patients: Evidence for saturable metabolism. Proc Am Soc Clin Oncol 13 (Abstr 371):144.
19. Shaw LM, Bonner HS, Schuchter L, Schiller J, and Lieberman R (1999) Pharmacokinetics of amifostine: Effects of dose and method of administration. Semin Oncol 26 (Suppl 7):34-36.
20. Shaw LM, Bonner H, Turrisi A, Norfleet AL, and Glover DJ (1984) A liquid chromatographic electrochemical assay for S-2-(3-aminopropylamino)ethylphosphoro-thioate (WR2721) in human plasma. J Liq Chromatogr 7:2447-2465.
21. Shaw LM, Bonner HS, Turrisi A, Norfleet AL, and Kligerman M (1986a) Measurement of S-2-(3-aminopropylamino)ethanethiol (WR1065) in blood and tissue. J Liq Chromatogr 9:845-859.
22. Shaw LM, Turrisi AT, Glover DJ, Bonner HS, Norfleet AL, Weiler C, and Kligerman MM (1986b) Human pharmacokinetics of WR-2721. Int J Radiat Oncol Biol Physiol 12:1501-1504.
23. Sigurdson ER, Ridge JA, Kemeny N, and Daly JM (1987) Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5:1836-1840.
24. Souid A-K, Newton GL, Dubowy RL, Fahey RC, and Bernstein ML (1998) Determination of the cytoprotective agent WR-2721 (Amifostine, Ethyol®) and its metabolites in human blood using monobromobimane fluorescent labeling and high-performance liquid chromatography. Cancer Chemother Pharmacol 42:400-406.
25. Spencer CM and Goa KL (1995) Amifostine: A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential as a radioprotector and cytotoxic chemoprotector. Drugs 50:1001-1031.
26. Swynnerton NF, Mangold DJ, and Ludden TM (1985) Measurement of ethiofos (WR 2721) in plasma: Preliminary pharmacokinetics in the beagle. J Liq Chromatogr 8:2675-2687.
27. Symon Z, Levi M, Ensminger WD, Smith DE, and Lawrence TS (2001) Selective radioprotection of hepatocytes by systemic and portal vein infusions of amifostine in a rat liver tumor model. Int J Radiat Oncol Biol Phys 50:473-478.
28. Wilkinson GR (1987) Clearance approaches in pharmacology. Pharmacol Rev 39:1-47.